Enterome Presents Immune-Monitoring Data on EO2401 at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
Read more
30
October 2023
Enterome Selected to The Leukemia & Lymphoma Society’s Therapy Acceleration Program
Read more
25
October 2023
Enterome to Present Clinical Progress on its OncoMimics™ Pipeline at Upcoming Investor Meetings
Read more
23
October 2023
Enterome Presents Positive Data from Phase 1/2 SPENCER Trial of EO2401 in Adrenal Tumors at ESMO 2023 Congress
Read more
16
October 2023
Enterome to Present Data on EO2401 in Adrenal Tumors at the European Society for Medical Oncology (ESMO) 2023 Congress
Read more
11
July 2023
Enterome announces first patient dosed in Phase 2 trial with OncoMimics™ immunotherapy EO2040 in Colorectal Cancer with ctDNA-defined Minimal Residual Disease
Read more
30
June 2023
Enterome announces first patient dosed in a Phase 1/2 trial with third OncoMimics™ immunotherapy, EO4010, in Metastatic Colorectal Cancer
Read more
16
June 2023
Enterome selected for the prestigious French Tech 2030 program designed to champion breakthrough technological innovations in France
Read more
14
June 2023
Enterome’s new OncoMimics™ immunotherapy, EO2463, demonstrates early efficacy and favorable safety in Phase 1/2 trial for indolent non-Hodgkin lymphoma
